Proprietary AI analyst is now available
- Public Comps
- Cathay Biotech
Cathay Biotech Valuation Multiples
Discover Cathay Biotech's revenue and EBITDA valuation multiples and investment history, alongside public comparables like UPL, Sumitomo Chemical, Wacker Chemie, Celanese and more.
Cathay Biotech Overview
About Cathay Biotech
Cathay Biotech Inc is engaged in research, development, production, and sales of new bio-based materials. The company owns the TERRYL brand, which focuses on bio-based polyamide fibers for textiles, and ECOPENT, which serves the engineering materials market.
Founded
2000
HQ

Employees
1.7K
Website
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trialCathay Biotech Financials
Cathay Biotech reported last 12-month revenue of $512M and EBITDA of $134M.
In the same LTM period, Cathay Biotech generated $177M in gross profit, $134M in EBITDA, and $98M in net income.
Cathay Biotech P&L
In the most recent fiscal year, Cathay Biotech reported revenue of $485M and EBITDA of $141M.
Cathay Biotech is profitable as of last fiscal year, with gross margin of 34%, EBITDA margin of 29%, and net margin of 17%.
Financial data powered by Morningstar, Inc.
Cathay Biotech Stock Performance
Cathay Biotech has current market cap of $5B, and enterprise value of $4B.
Cathay Biotech's stock price is $7.34.
Cathay Biotech has an EPS (earnings per share) of $0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $5B | -0.7% | - | - | - | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCathay Biotech Valuation Multiples
Cathay Biotech trades at 8.0x EV/Revenue multiple, and 30.3x EV/EBITDA.
Cathay Biotech Financial Valuation Multiples
As of June 26, 2026, Cathay Biotech has market cap of $5B and EV of $4B.
Cathay Biotech has a P/E ratio of 54.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cathay Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Cathay Biotech Margins & Growth Rates
Cathay Biotech grew revenue by 12% and EBITDA by 7% in the last fiscal year.
In the most recent fiscal year, Cathay Biotech reported gross margin of 34%, EBITDA margin of 29%, and net margin of 17%.
Cathay Biotech Margins
Cathay Biotech Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Cathay Biotech Operational KPIs
Cathay Biotech's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.
Cathay Biotech's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cathay Biotech's Rule of X is 58% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Cathay Biotech Competitors
Cathay Biotech competitors include UPL, Sumitomo Chemical, Wacker Chemie, Celanese, Fuchs, Sensient Technologies, Balchem, Xin Feng Ming Group, IMCD and USA Rare Earth.
Most Cathay Biotech public comparables operate across Advanced Materials, Chemicals, Bioindustrials, DeepTech, BioTech and AgriTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.3x | 1.3x | 6.7x | 6.7x | |||
| 0.7x | 0.7x | 5.8x | 6.2x | |||
| 1.0x | 1.0x | 12.6x | 10.1x | |||
| 1.7x | 1.7x | 8.7x | 8.2x | |||
| 1.3x | 1.3x | 8.9x | 8.8x | |||
| 3.7x | 3.5x | 20.2x | 18.9x | |||
| 5.3x | 5.2x | 20.2x | 19.3x | |||
| 0.8x | 0.8x | 11.1x | 9.2x | |||
This data is available for Pro users. Sign up to see all Cathay Biotech competitors and their valuation data. Start Free Trial | ||||||
Investments by Cathay Biotech
Cathay Biotech has invested in 1 company to date.
Latest investment by Cathay Biotech was on June 16th 2026. Cathay Biotech invested in MoleculeMind in their $86M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Cathay Biotech
| Description | MoleculeMind is a Hangzhou-based AI platform for de novo protein design. The system employs generative models to engineer novel enzymes and therapeutic proteins, optimizing sequences for stability and function. Applications span antibody engineering, vaccine antigens, and industrial biocatalysts, accelerating discovery cycles for biotech firms targeting metabolic disorders and crop protection agents. | MoleculeMind is a Hangzhou-based AI platform for de novo protein design. The system employs generative models to engineer novel enzymes and therapeutic proteins, optimizing sequences for stability and function. Applications span antibody engineering, vaccine antigens, and industrial biocatalysts, accelerating discovery cycles for biotech firms targeting metabolic disorders and crop protection agents. |
| HQ Country | ||
| HQ City | Beijing | Beijing |
| Deal Date | 16 Jun 2026 | 20 Feb 2023 |
| Round | Series A | Seed |
| Raised | $86M | $15M |
| Investors | Oriental Fortune Capital; Cathay Biotech; Infinity Equity; Caixin Capital; Core Air Capital; Suzhou Sepax Technologies; Guofang Venture Capital; Pudong Chuangtou; COFCO; Blue Bridge Capital; Fosun Capital; Zhong Xin Hang Capital Management; Eastern Bell Capital | Cathay Biotech; Lenovo Capital and Incubator Group (LCIG); HSG |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Cathay Biotech investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cathay Biotech
| When was Cathay Biotech founded? | Cathay Biotech was founded in 2000. |
| Where is Cathay Biotech headquartered? | Cathay Biotech is headquartered in China. |
| How many employees does Cathay Biotech have? | As of today, Cathay Biotech has over 1K employees. |
| Is Cathay Biotech publicly listed? | Yes, Cathay Biotech is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Cathay Biotech? | Cathay Biotech trades under 688065 ticker. |
| When did Cathay Biotech go public? | Cathay Biotech went public in 2020. |
| Who are competitors of Cathay Biotech? | Cathay Biotech main competitors include UPL, Sumitomo Chemical, Wacker Chemie, Celanese, Fuchs, Sensient Technologies, Balchem, Xin Feng Ming Group, IMCD, USA Rare Earth. |
| What is the current market cap of Cathay Biotech? | Cathay Biotech's current market cap is $5B. |
| What is the current revenue of Cathay Biotech? | Cathay Biotech's last 12 months revenue is $512M. |
| What is the current revenue growth of Cathay Biotech? | Cathay Biotech revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Cathay Biotech? | Current revenue multiple of Cathay Biotech is 8.0x. |
| What is the current EBITDA of Cathay Biotech? | Cathay Biotech's last 12 months EBITDA is $134M. |
| What is Cathay Biotech's EBITDA margin? | Cathay Biotech's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Cathay Biotech? | Current EBITDA multiple of Cathay Biotech is 30.3x. |
| How many companies Cathay Biotech has acquired to date? | Cathay Biotech hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Cathay Biotech has invested to date? | As of June 2026, Cathay Biotech has invested in 1 company. |
| What was the last Cathay Biotech investment? | On 16th June 2026 Cathay Biotech invested in MoleculeMind, participating in a $86M Series A round, alongside Oriental Fortune Capital, Infinity Equity, Caixin Capital, Core Air Capital, Suzhou Sepax Technologies, Guofang Venture Capital, Pudong Chuangtou, COFCO, Blue Bridge Capital, Fosun Capital, and 2 other investors. |
| In what companies Cathay Biotech invested in? | Cathay Biotech invested in MoleculeMind. |
See public comps similar to Cathay Biotech
Lists including Cathay Biotech
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
